This article has Open Peer Review reports available.
Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma
© The Author(s). 2017
Received: 10 January 2016
Accepted: 8 December 2016
Published: 29 December 2016
This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients.
We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS).
Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. P-values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group).
Adding vertebral augmentation to conventional therapy improves multiple myeloma patients’ quality of life, but didn’t affect the mortality rate.
KeywordsMultiple myeloma Vertebral augmentation Vertebroplasty Kyphoplasty Chemotherapy Radiotherapy Spine Outcomes
Multiple myeloma is accumulation of malignant plasma cell in the bone marrow leading to impaired blood cell formation and multiple lytic lesions in the skeleton. The incidence of bone involvement is about 70–100% while vertebral column is about 60% [1–3]. Bone becomes week and easy to fracture, which may cause pain in the bone and inability to use the limb. In the spine, fractured vertebra causes pain, kyphotic or kyphoscoliotic deformity, compression of the spinal cord or cauda equina in addition to the general symptoms of multiple myeloma [1, 3].
General treatment of the disease includes radiotherapy, chemotherapy and bisphosphonate to decrease bone resorption in addition to analgesia, bed rest and bracing to treat pathological fractures . Minimally-invasive vertebroplasty and balloon kyphoplasty are used as local treatment of the vertebral lesions to decrease pain and prevent or treat deformities [3–5]. Vertebroplasty is insertion of bone cement (polymethylmetacrylate) inside the vertebral body using pedicle cannula unilaterally or bilaterally while balloon kyphoplasty is insertion of balloon tamps through pedicle cannulae to reduce the height of the vertebra, realign the sagittal plane and create a cavity for bone cement [6–8]. Many studies were concentrating on multilevel vertebroplasty and kyphoplasty to treat multiple myeloma, but not more than 6 and 8 levels [9, 10].
At our hospital, we used vertebral augmentation in the management of multiple myeloma in a different way. We perform multilevel vertebral augmentation for all vulnerable vertebrae; thoracic, lumbar and sometimes the first sacral vertebra. Our practice is to not wait until the vertebra collapsed as a cause of the tumor, which may lead to neurological sequelae. As such, the following prospective study evaluated the outcomes of our multiple myeloma patients who underwent multilevel vertebral augmentation in addition to conventional therapy.
This is a prospective study of effectiveness of the addition of vertebral augmentation to conventional chemotherapy and radiotherapy in treating multiple myeloma patients. Our main aims were to prevent spinal column collapse, back deformity, neurological deficits, minimize pain and decrease general morbidities.
- Group I:
13 patients were treated by conventional treatment (i.e. chemotherapy and radiotherapy) (Table 1).
- Group II:
14 patients; 206 vertebrae, number of vertebrae ranged between 10 and 16 (mean: 14.7); were treated by vertebral augmentation in addition to conventional therapy (five patients with chemotherapy and radiotherapy and nine patients with chemotherapy) (Table 1). One patient needed radiotherapy post augmentation.
Demographic and clinical characteristics of patients according to method of treatment
Number of patients
39–78 (Mean: 58.15, SD: 12.3)
34–74 (Mean: 58.86, SD: 11.99)
Sex (Male : Female)
Chemo and Radiotherapy = 7
Chemotherapy = 6
Vertebroplasty and Kyphoplasty
Two hundred six vertebrae (one patient 10 v, one patient 12 v, three patients 14 v, two patients 15, and seven patients 16 vertebrae) in addition to Chemotherapy or Chemo and Radiotherapy
Patients who had spinal canal extension or spinal cord compromise, cauda equine compression, late-stage disease and patients who are previously underwent spinal surgery were excluded. International scoring and questionnaire systems consisting of the Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS) were used to evaluate the clinical and radiological results. The patients were evaluated clinically and radiographically on discharge-day, 6, 12, 24 and 36 months.
Statistically, we used SPSS version 20 (Chicago, IL, USA) to evaluate the results. Levene’s test for equality of variances was used to evaluate patients at each follow-up interval. This test gives mean values, standard deviation and p-value. Test of between-subjects effect, transformed variables: Average using ANOVA Method to evaluate the end results.
We treated 27 patients, whom were recently diagnosed with multiple myeloma. There were 13 patients in group I (conventional treatment) and 14 patients in group II (n = 206 vertebrae, vertebral augmentation group). Mean age for group I was 58.2 years, mean follow-up was 36 months and male to female ratio was 9:4. For group II, the mean age was 58.9 years, the mean follow-up was 36 months and male to female ratio was 6:8. There was no significant statistical difference in the age between two groups as shown in Table 1.
Morbidity and mortality of each group
Threepatients bed ridden due to multiple spinal fracture and paraparesis.
Four patients can walk with aid
All still mobile without aid except one who needs stalk aid.
Five patients: four deaths due to advancement of the disease and one due to sepsis after 7–11 months of treatment (38.5%)
one at the same day of surgery due to PE,
two after 1.5 year of treatment due to advancement of the disease and one after 1.5 years due to pneumonia. (27.3%)
Back Pain Improvement
Six patients improved partially
All patients improved after Vertebroplasty with three of them had episodes of pain.
Vertebroplasty Intraoperative Complications
One had small leak toward the spinal canal without neurological disorders.
One had intravascular leak.
There were few intraoperative complications in group II. Cement leak inside the spinal canal with no significant neurological compromise or deficits occurred in one patient and intravascular leak in a small vessel was seen in two patients (Figs. 5 and 6). Bone cement didn’t affect chemotherapy or radiotherapy.
Oswestry Disability Index, Stanford score and the Spinal Instability Neoplastic Score values were nearly equal in both groups before treatment. ODI of group I was 31.9 (63.8%) with SD = 8.34 and of group II was 33.2 (66.4%) with SD = 5.98 (p = 0.418). SS of group I was 4.3 (SD = 2.6) and of group II was 4.6 (SD = 2.9) (p = 0.309). SINS of group I was 13.8 (SD = 2.9) and of group II was 12.8 (SD = 2.9) (p = 0.482).
At 6 months-follow up, group II value improved, ODI mean values were 32.5 (64.9% and SD = 10.92) and 23.14 (46.28% and SD = 8.49) for group I and II, respectively (p = 0.316). The SS value was 5.26 (SD 2.96) for group I and 7.18 (SD 1.39) for group II (p = 0.05). SINS was 12.85 (SD 2.79) for group I and 7.15 SD 3.24 for group II (p = 0.449).
At 1 year follow-up, group I score values showed more improvement. ODI value for group I was 28.4 (56.8%) with SD = 8.79 and for group II was 21.4 (42.8%) with SD = 9.24 (p = 0.874). The SS value for group I was 5.28 with SD 2.88 and for group II was 7.52 with SD 1.48 (p = 0.012). SINS value for group I was 12.85 with SD 2.88 and for group II was 7.23 with SD 3.37 (p = 0.526).
At 2 years follow-up, ODI for group I was 28.42 (56.85%) with SD 8.79 and for group II was 21.43 (42.65%) with SD 9.24 (p = 0.874). The SS for group I was 5.40 with SD 2.83 and for group II was 7.68 with SD 1.56 (p = 0.047). SINS value for group I was 12.75 with SD 2.67 and for group II was 7.31 with SD 3.43 (p = 0.278).
At 3 years follow-up, ODI for group I was 29.17 (58.34%) with SD = 9.37 and for group II was 21.43 (42.86%) with SD 9.931 (p = 0.840). The SS mean value for group I was 5.27 with SD 2.94 and for group II was 7.83 with SD 1.64 (p = 0.040). SINS mean value for group I was 12.58 with SD 2.75 and for group II was 7.36 with SD = 3.72 a (p = 0.121).
At the end of the study (3 years), we used test of between-subjects effect, transformed variables: average using ANOVA method to compare the end results of each group. ODI and SINS showed significant difference between two groups (p = 0.047 and p = 0.002) with less significant difference by using SS (p = 0.180). All group II were freely mobile except one who used a cane when walk. All patients were back pain free except three, who had number of exacerbations of pain that may be attributed to disc disease or fracture of vertebral end plate over bone cement. All patients had preserved vertebral height and sagittal balance except for one who had history of inter-scapular pain 4 years after surgery and x-rays showed mild loss of height of T4 around the bone cement which was insignificant as compared to three patients of group I who became bedridden due to vertebral fractures with involvement of the spinal canal.
Postoperative intervals in relation to outcome scores
In the literature review addressing previous studies discussing multilevel vertebral augmentation, we found that most of them were dealing with less than eight levels and were performed in more than one surgical session [9, 18]. Two case reports were found with multilevel vertebral augmentation. The first one was used to treat newly adjacent level fractures in a patient who was treated for osteoporotic fracture . The second case was treated for multiple osteoporotic fractures that occurred at different times after vertebroplasty in a patient with chronic liver disease .
In our study, all the patients had the same disease, were treated by the same hematologist, all procedures were done by the same spine surgeon and evaluated by independent physicians. In group II, 14 patients (206 vertebrae), who underwent vertebral augmentation, the procedures were done at same session for all involved vertebra for single patient. This decreased the need and risk of repetitive anesthesia, although increased the operative time and radiological exposure. We did several measures to decrease surgical time and radiological exposure, inserting a working cannula directly (eliminating introducing cannula and K wire need), inserting multiple cannulas at the same time and using unilateral cannula at T9 and above. In addition, there was no significant statistical difference of mortality rate between the two groups.
Multilevel vertebral augmentation in addition to conventional therapy showed superior results as compared with conventional therapy alone. It relieves pain, preserves vertebral height, sagittal balance and improves mobility of the patients. There was no significant difference of mortality rates between the two groups, but there was significant improvement of morbidity rates. The limitation of this study was the small sample size and variable follow-up periods. Larger, prospective studies are needed to further assess the outcome of such treatment modalities in multiple myeloma patients.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. IRB (Institutional Research Committee) of Jordan University of Sceince & Technoloy agreement number 218-2014 was obtained.
ZA Corresponding author, participated in study design, review of the literature and patient information collection. MH Participated in study design and pre and postop medical management. MF Participated in study design and review of literature. KA Participated in study design and pre and postop medical management. MO Participated in study design and statistics. MB Participated in study design and review of literature. AA Participated in study design. RJ Participated in patient evaluation and study design. MK Participated in data collection and statistics. MA Participated in data collection and statistics.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- La Maida GA, Sala F, Callea G, et al. Efficacy of unipedicular balloon kyphoplasty for treatment of multiple myeloma vertebral lesions. Asian Spine J. 2011;5:162–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Lecouvet FE, Vande Berg BC, Maldague BE, et al. Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. Radiology. 1997;204:195–9.View ArticlePubMedGoogle Scholar
- Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol. 2002;20:2382–7.View ArticlePubMedGoogle Scholar
- Lavanga A, Guarnieri G, Muto M. Medical therapy and multilevel vertebroplasty in osteoporosis: when and why. Neuroradiol J. 2010;23:244–8.View ArticlePubMedGoogle Scholar
- Lane J, Hong R, Koob J, et al. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Rel Res. 2004;426:49–53.View ArticleGoogle Scholar
- Jensen ME, Evans AJ, Mathis JM, Kallmes DF, Cloft HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral compression fractures: technical aspects. Am J Neuroradiol. 1997;18:1897–904.PubMedGoogle Scholar
- Galibert P, Deramond H, Rosat P, Le Gars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. Neurochirurgie. 1987;33:166–8.PubMedGoogle Scholar
- McArthur N, Kasperk C, Baier M, et al. 1150 kyphoplasties over 7 years: indications, techniques, and intraoperative complications. Orthopedics. 2009;32:90.PubMedGoogle Scholar
- Mailli L, Filippiadis DK, Brountzos EN, et al. Clinical outcome and safety of multilevel vertebroplasty: clinical experience and results. Cardiovasc Intervent Radiol. 2013;36:183–91.View ArticlePubMedGoogle Scholar
- Katonis P, Hadjipavlou A, Souvatzis X, et al. Respiratory effects, hemodynamic changes and cement leakage during multilevel cement balloon Kyphoplasty. Eur Spine J. 2012;21:1860–6.View ArticlePubMedPubMed CentralGoogle Scholar
- McDonald RJ, Trout AT, Gray LA, et al. Vertebroplasty in multiple myeloma: outcomes in a large patient series. AJNR Am J Neuroradiol. 2008;29:642–8.View ArticlePubMedGoogle Scholar
- Masala S, Anselmetti GC, Marcia S, et al. Percutaneous vertebroplasty in multiple myeloma vertebral involvement. J Spinal Disord Tech. 2008;21:344–8.View ArticlePubMedGoogle Scholar
- Dunn J. Percutaneous vertebroplasty in the management of a patient with malignant pain and associated osteolytic compression fractures. Curr Pain Headache Rep. 2002;6:436–43.View ArticlePubMedGoogle Scholar
- Yang Z, Xu J, Sang C. Clinical studies on treatment of patients with malignant spinal tumors by percutaneous vertebroplasty under guidance of digital subtraction angiography [in Chinese]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2006;20:999–1003.PubMedGoogle Scholar
- Ryska P, Rehak S, Odraka K, et al. Role of percutaneous vertebroplasty and kyphoplasty in the treatment of oncology disorders of the spine [in Czech]. Cas Lek Cesk. 2006;145:804–9.PubMedGoogle Scholar
- O’Brien J, Brennan D, Taylor D, et al. Percutaneous vertebroplasty–initial clinical experience in osteoporotic and myelomatous compression fractures. Ir J Med Sci. 2006;175:50–3.View ArticlePubMedGoogle Scholar
- Bartolozzi B, Nozzoli C, Pandolfo C, et al. Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma. Eur J Haematol. 2006;76:180–1.View ArticlePubMedGoogle Scholar
- Graya LA, Ehteshami Rada A, et al. Efficacy of percutaneous vertebroplasty for multiple synchronous and metachronous vertebral compression fractures. AJNR Am J Neuroradiol. 2009;30:318–22.View ArticleGoogle Scholar
- Kim HW, Song JW, et al. Extreme multi-level percutaneous vertebroplasty for newly developed multiple adjacent compression fractures. J Korean Neurosurg Soc. 2009;45:378–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Karatoprak O, Camurdan K, et al. Multiple-level cement vertebroplasty in patients with vertebral compression fractures from osteodystrophy in chronic liver disease. Acta Orthop Belg. 2008;74:566–8.PubMedGoogle Scholar